Table 5 Clinicopathologic characteristics according to MSI status
From: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
| Â | Patients with MSI status | p-value | ||
|---|---|---|---|---|
MSS/MSI-L | MSI-H | total | ||
(NÂ =Â 77) | (NÂ =Â 6) | (NÂ =Â 83) | ||
Sex | Â | Â | Â | 0.482 |
 Male | 44 (57.1%) | 2 (33.3%) | 46 (55.4%) |  |
 Female | 33 (42.9%) | 4 (66.7%) | 37 (44.6%) |  |
Age | Â | Â | Â | 0.608 |
  < 50 year | 13 (16.9%) | 0 (0.0%) | 13 (15.7%) |  |
  ≥ 50 year | 64 (83.1%) | 6 (100.0%) | 70 (84.3%) |  |
Location | Â | Â | Â | 0.037 |
 Rt colon | 18 (23.4%) | 4 (66.7%) | 22 (26.5%) |  |
 Lt colon | 39 (50.6%) | 1 (16.7%) | 40 (48.2%) |  |
 Rectum | 17 (22.1%) | 0 (0.0%) | 17 (20.5%) |  |
 Multiple | 3 (3.9%) | 1 (16.7%) | 4 (4.8%) |  |
Stage | Â | Â | Â | 0.642 |
 StageI | 14 (18.2%) | 2 (33.3%) | 16 (19.3%) |  |
 StageII | 27 (35.1%) | 2 (33.3%) | 29 (34.9%) |  |
 StageIII | 36 (46.8%) | 2 (33.3%) | 38 (45.8%) |  |
T stage | Â | Â | Â | 0.984 |
 T1 | 9 (11.7%) | 1 (16.7%) | 10 (12.0%) |  |
 T2 | 13 (16.9%) | 1 (16.7%) | 14 (16.9%) |  |
 T3 | 39 (50.6%) | 3 (50.0%) | 42 (50.6%) |  |
 T4 | 16 (20.8%) | 1 (16.7%) | 17 (20.5%) |  |
N stage | Â | Â | Â | 0.788 |
 N0 | 41 (53.2%) | 4 (66.7%) | 45 (54.2%) |  |
 N1 | 14 (18.2%) | 1 (16.7%) | 15 (18.1%) |  |
 N2 | 22 (28.6%) | 1 (16.7%) | 23 (27.7%) |  |
Lymphatic invasion | Â | Â | Â | 0.971 |
 Absent | 46 (59.7%) | 3 (50.0%) | 49 (59.0%) |  |
 Present | 31 (40.3%) | 3 (50.0%) | 34 (41.0%) |  |
Venous invasion | Â | Â | Â | 0.378 |
 Absent | 58 (75.3%) | 6 (100.0%) | 64 (77.1%) |  |
 Present | 19 (24.7%) | 0 (0.0%) | 19 (22.9%) |  |
Perineural invasion | Â | Â | Â | 0.248 |
 Absent | 53 (68.8%) | 6 (100.0%) | 59 (71.1%) |  |
 Present | 24 (31.2%) | 0 (0.0%) | 24 (28.9%) |  |
Differentiation | Â | Â | Â | 0.012 |
 Well | 13 (17.8%) | 0 (0.0%) | 13 (16.9%) |  |
 Moderate | 59 (80.8%) | 3 (75.0%) | 62 (80.5%) |  |
 Poor | 1 (1.4%) | 1 (25.0%) | 2 (2.6%) |  |
Histology | Â | Â | Â | <0.001 |
 Non-mucinous adenocarcinoma | 72 (93.5%) | 1 (16.7%) | 73 (88.0%) |  |
 Mucinous adenocarcinoma | 5 (6.5%) | 5 (83.3%) | 10 (12.0%) |  |
Recur | Â | Â | Â | 0.608 |
 Recur | 64 (83.1%) | 6 (100.0%) | 70 (84.3%) |  |
 Non-recur | 13 (16.9%) | 0 (0.0%) | 13 (15.7%) |  |
Expire | Â | Â | Â | 1 |
 Expire | 71 (92.2%) | 6 (100.0%) | 77 (92.8%) |  |
 Non-Expire | 6 (7.8%) | 0 (0.0%) | 6 (7.2%) |  |
BRAF status | Â | Â | Â | 0.326 |
 Wild type | 76 (98.7%) | 5 (83.3%) | 81 (97.6%) |  |
 Mutation | 1 (1.3%) | 1 (16.7%) | 2 (2.4%) |  |
KRAS status | Â | Â | Â | 0.102 |
 Wild type | 44 (57.1%) | 6 (100.0%) | 50 (60.2%) |  |
 Mutation | 33 (42.9%) | 0 (0.0%) | 33 (39.8%) |  |